RHEUMATOLOGY

Original article

Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study

Dawit T. Zemedikun ()¹, Krishna Gokhale¹, Joht Singh Chandan ()^{1,2}, Jennifer Cooper¹, Janet M. Lord^{3,4}, Andrew Filer³, Marie Falahee³, Krishnarajah Nirantharakumar^{1,*} and Karim Raza^{3,4,5,*}

Abstract

Objective. To compare the incident risk of RA in patients with type 2 diabetes mellitus (T2DM) and to explore the role of glycaemic control and associated therapeutic use in the onset of RA.

Methods. This study was a retrospective cohort study using patients derived from the IQVIA Medical Research Data (IMRD-UK) database between 1995 and 2019. A total of 224 551 newly diagnosed patients with T2DM were matched to 449 101 patients without T2DM and followed up to assess their risk of RA. Further analyses investigated the effect of glycaemic control, statin use and anti-diabetic drugs on the relationship between T2DM and RA using a time-dependent Cox regression model.

Results. During the study period, the incidence of RA was 8.1 and 10.6 per 10 000 person-years in the exposed and unexposed groups, respectively. The adjusted hazard ratio (aHR) was 0.73 (95% CI 0.67, 0.79). In patients who had not used statins in their lifetime, the aHR was 0.89 (95% CI 0.69, 1.14). When quantifying the effects of gly-caemic control, anti-diabetic drugs and statins using time-varying analyses, there was no association with glycaemic control [aHR 1.00 (95% CI 0.99, 1.00)], use of metformin [aHR 1.00 (95% CI 0.82, 1.22)], dipeptidyl peptidase-4 inhibitors [DPP4is; aHR 0.94 (95% CI 0.71, 1.24)] and the development of RA. However, statins demonstrated a protective effect for progression of RA in those with T2DM [aHR 0.76 (95% CI 0.66, 0.88)], with evidence of a duration–response relationship.

Conclusion. There is a reduced risk of RA in patients with T2DM that may be attributable to the use of statins.

Key words: type 2 diabetes, rheumatoid arthritis, epidemiology, electronic health records

Rheumatology key messages

- There is a reduced risk of RA in patients with type 2 diabetes compared with non-diabetic controls.
- The use of metformin and/or DPP4i did not influence the risk of RA in patients with type 2 diabetes.
- Statin use in patients with type 2 diabetes was associated with a significantly reduced risk of RA.

¹Institute of Applied Health Research, University of Birmingham, Birmingham, ²Warwick Medical School, University of Warwick, Coventry, ³Institute of Inflammation and Ageing, ⁴MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, University of Birmingham and ⁶Sandwell and West Birmingham NHS Hospitals Trust, Birmingham, UK

Submitted 25 November 2020; accepted 30 January 2021

Correspondence to: Krishnarajah Nirantharakumar, Institute of Applied Health Research, University of Birmingham, Birmingham,B15 2TT, UK. E-mail: k.nirantharan@bham.ac.uk

*Krishnarajah Nirantharakumar and Karim Raza contributed equally to this article.

Introduction

RA is a common chronic inflammatory disease of multifactorial aetiology associated with systemic inflammation [1]. RA affects >400 000 people in the UK [2], with an annual incidence estimated at 3.8 cases per 10 000 population [3]. Common symptoms include joint pain, swelling and stiffness, often accompanied by fatigue. Persistent inflammation leads to joint erosion and a loss of function. Extra-articular features, including cardiometabolic and pulmonary disease, are common, even at an early stage [4]. A third of people with RA stop working

in any medium, provided the original work is properly cited.

[©] The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction

within 2 years and half are unable to work within 10 years [5].

There is currently no cure for RA, and long-term treatment with DMARDs is usually required to limit disease progression [6]. The potential toxicity and high cost associated with many of these treatments has led to considerable effort to understand the causes of RA and the pathology of its earliest phases with a view to developing preventive interventions [7].

A range of modifiable environmental risk factors are associated with RA [8], with cigarette smoking having the strongest evidence base [9, 10]. A wide range of genetic factors are also known to contribute to the risk of RA [11]. Shared genetic risk factors between RA and other autoimmune diseases such as type 1 diabetes [12-14] explain the documented association between these conditions [15-17]. Current literature suggests that patients with RA have an increased risk of type 2 diabetes mellitus (T2DM) [18], although this association was not evident when controlled for underlying BMI [19]. Interestingly, this relationship may be influenced by medications used in patients with RA [20]. Drugs prescribed in RA modulate diabetes risk with HCQ [21], abatacept [21] and anti-TNF therapy [22] reducing the risk of DM, while glucocorticoids are associated with an increased risk [21].

In contrast, there is limited evidence for an increased risk of RA following a diagnosis of T2DM. One may hypothesize that RA would be more common in patients with T2DM due to shared risk factors, including obesity, metabolic syndrome and chronic low-grade inflammation [23, 24]. A cross-sectional study from Taiwan found a 46% higher risk of developing RA in women but not in men with a diagnosis of T2DM [25]. The European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register (EPIC-2-NOAR), a longitudinal community-based study, reported a 2.5-fold increased risk of inflammatory polyarthritis in patients with selfreported diabetes, but type 1 and 2 diabetes were not differentiated. Furthermore, only 11 patients who developed inflammatory polyarthritis had diabetes at baseline [26].

Many drugs used to treat T2DM have immunomodulatory properties, and those need to be taken into account when exploring the risk of RA in patients with T2DM. For example, dipeptidyl peptidase-4 inhibitors (DDP4is) achieve their anti-hyperglycaemic effect through prevention of DDP4-mediated degradation of incretin hormones [including glucagon-like peptide-1 (GLP-1)]. In addition to their anti-hyperglycaemic effects, DPP4is also have anti-inflammatory properties [27]. Two studies using insurance claims-based data suggested a 33% reduced risk of RA in patients treated with DPP4is, although those studies failed to adjust for important confounders, including BMI [28, 29]. A subsequent time-dependent analysis using the Clinical Practice Research Datalink (CPRD), which adjusted for known risk factors for RA including BMI and smoking status, demonstrated no evidence of association between DPP4is and the incidence

of RA [hazard ratio (HR) 1.0 (95% CI 0.8, 1.3)] [30]. The use of metformin, which also has anti-inflammatory properties [31], has been associated with a reduced risk of RA [32]. Previous studies assessing the effects of statins on RA development have reported conflicting results, with one study reporting an increased risk [33] and others reporting a reduced risk [34, 35]. A recent systematic review identified no difference in RA risk between statin users and non-users, although methodological limitations of the included studies were identified [36]. However, the effect of statins on RA risk in patients with T2DM remains unknown.

We therefore aimed to provide a definitive answer to the question of whether T2DM is associated with an increased onset of RA and to explore the role of glycaemic control in the risk of RA and whether antidiabetic drugs (oral and injectable) and lipid-lowering drugs (specifically statins) influence the risk of RA.

Methods

Study design and data source

This study was a population-based retrospective open cohort study using patient data derived from the IQVIA Medical Research Data (IMRD-UK), formerly the Health Improvement Network (THIN) database. The IMRD-UK is a nationally representative electronic primary care database that contains pseudo-anonymized medical records for >15 million patients derived from 808 general practices in the UK. The IMRD-UK has been demonstrated to be representative of the UK population in terms of demographic structure and common morbidity prevalence [37]. The database has been used in numerous epidemiological studies to examine health outcomes in T2DM [38-40] and RA [41, 42]. Information relating to symptoms, examinations, investigations and diagnoses are recorded within the IMRD-UK as Read codes, a clinical hierarchy coding system [43]. To reduce underrecording of events and improve data quality, general practices were included 12 months after they installed electronic medical records or from the practice's acceptable mortality recording (AMR) date [44-46].

Study population, exposure and outcome

The study period was set between 1 January 1995 and 31 December 2019. Adult patients ≥18 years of age registered for at least 12 months with any of the eligible practices formed the source population. The exposed cohort consisted of incident cases (newly diagnosed patients) with T2DM. Exposure to T2DM was ascertained by the presence of Read codes indicative of diag-(Supplementary Table S1, available at nosis Rheumatology online) in the patient's medical record and the absence of any type 1 diabetes diagnostic code. The outcome, RA, was also defined on the basis of Read codes (Supplementary Table S1, available at Rheumatology online). Codes relating to diabetes and the outcome of RA are part of the Quality Outcomes

Framework (QOF), a payment incentivized coding system for general practitioners (GPs) within the UK [47]. These diagnoses have been validated in primary care settings [48]. Each exposed patient was matched to up to two unexposed control patients who were randomly selected from an age- and sex-matched pool of eligible patients without a record of T2DM at any time.

Follow-up period

The index date for the exposed patients was the date of the first recorded Read code relating to T2DM exposure once a patient was eligible to take part in the study. To avoid immortal time bias [49], the same index date was assigned to the corresponding unexposed patient. Both exposed and unexposed patients were followed up from the index date until the earliest of the following endpoints that defined the exit date: outcome (RA) date, study end date, last date of data collection from a given GP, date patient transferred from GP and death date.

A 15 month latency period (lag period ensuring the index date was set 15 months following the date of diagnosis) was included in the selection of exposed patients. This was to ensure that all covariates predicting the risk of RA in patients with T2DM were recorded at baseline as per QOF guidelines [50, 51]. The latency period also limited the possibility of silent RA preceding T2DM being misclassified as incident RA, reducing the likelihood of reverse causality in our study.

Effect on RA risk of glycaemic control and medication in patients with DM

In order to account for the differential impact of medications (defined through drug codes) acting as modifiers along the pathway, three variations of the study design were used to examine the relationship between T2DM and the risk of developing RA.

The first study included all eligible exposed patients who were matched by age (± 1 year) and sex to up to two unexposed patients. The aim of this study was to look at the overall risk of RA in newly diagnosed patients with T2DM.

The second study aimed at assessing the impact of statin use on the onset of RA by replicating the first study, but in patients who at no time point in the database had a prescription for statins (both in exposed and unexposed patients).

A time-dependent approach was adopted in the third study by taking only patients with prescribed antidiabetic medication from the first study. In this study, patients entered the cohort on receiving a prescription of an anti-diabetic drug. Longitudinal measurements during the study period were collected for these patients to assess the effect of glycaemic control and differential effects of anti-diabetic drugs (particularly metformin) and statins on subsequent RA risk.

Covariates

Known confounders and relevant covariates based on biological plausibility were used in the adjusted analyses. These included age, sex, BMI, smoking status, ethnicity and deprivation assessed by the Townsend deprivation quintiles. The Townsend score is calculated using social indices such as income, education and employment. All baseline data used were the latest recorded on the index date and all subsequent records until the patients exited the study (for time-varying covariates). In the third variation of the study, glycaemic control, statins and anti-diabetic drugs were treated as time-varying covariates measured in 3 month intervals.

Statistical analysis

Baseline characteristics of the cohorts were reported using appropriate descriptive statistics. In order to calculate an incidence rate (IR) per 10 000 person-years (py) for each of the outcomes of interest, patients with pre-existing RA were excluded when extracting data to ensure the IR reflected outcomes that occurred following cohort entry. Cox regression was used in the static models (studies 1 and 2: matched overall cohort and cohort devoid of statin use) to calculate crude and adjusted HRs (aHRs) together with their corresponding 95% CIs comparing the incidence of RA in patients with and without T2DM. Subgroup analyses were conducted to assess sex-specific differences.

We used extended Cox proportional hazards models in the time-dependent analyses (study 3). Time-varying covariance occurs when a given covariate changes as a function of time during the follow-up period [52]. The main approach for survival analysis with a time-varying covariate is time-dependent Cox regression modelling, which extends the Cox proportional hazard model to allow time-varying covariates [53]. For this, it was essential to organize the data in a counting process style with a fixed follow-up interval (3 months in this case) for each individual. In the primary model we assessed the effect of glycaemic control [haemoglobin A1c (HbA1c)], metformin against any other oral hypoglycaemic agent and statin use against the absence of a prescription for a statin. Thereafter, to validate our finding, we used the same method but with DPP4i as the exposure of interest instead of metformin. DPP4i has been previously shown to have no effect on the risk of RA in a time-dependent analysis from a similar database [30].

We conducted a sensitivity analysis in the timedependent analysis for metformin by adding a 3 month lag (one interval) period for drug exposures. This meant that outcomes were considered in the following 3 month interval for the current exposure period to allow sufficient time for the drugs to have an effect. A further sensitivity analysis was performed to assess durationresponse relations based on the cumulative duration of statin use. This categorical time-varying variable was defined as the time between the first-ever statin prescription and the time of the event. We used R version 3.4.1 (R Foundation for Statistical Computing, Vienna,

TABLE 1 Baseline characteristics of the study population

Characteristics	Exposed (<i>n</i> = 224 551)	Unexposed (<i>n</i> = 449 101)
Sex, <i>n</i> (%)		
Male	125 558 (55.92)	251 116 (55.92)
Female	98 993 (44.08)	197 985 (44.08)
Age, years, mean (s.d.)	63.10 (13.16)	63.08 (13.17)
Age categories (years), n (%)		
18–34	3786 (1.69)	7651 (1.70)
35–44	15 352 (6.84)	30 847 (6.87)
45–54	39 947 (17.79)	80 020 (17.82)
55–64	59 087 (26.31)	118 253 (26.33)
65–74	59 844 (26.65)	119 284 (26.56)
≥75	46 535 (20.72)	93 046 (20.72)
BMI, kg/m², median (IQR)	30.00 (26.00–34.00)	26.00 (23.00–29.00)
BMI categories (kg/m²), <i>n</i> (%)		
Underweight (<18.5)/normal weight (18.5–24.9)	30 340 (13.51)	144 989 (32.28)
Overweight (25–29.9)	72 597 (32.33)	149 227 (33.23)
Obese (≥30)	116 343 (51.81)	83 335 (18.56)
Missing or implausible	5271 (2.35)	71 550 (15.93)
Townsend quintiles, <i>n</i> (%)		
1 (least deprived)	41 356 (18.42)	102 212 (22.76)
2	39 613 (17.64)	88 768 (19.77)
3	41 212 (18.35)	79 011 (17.59)
4	38 484 (17.14)	63 307 (14.10)
5 (most deprived)	29 271 (13.04)	42 484 (9.46)
Missing	34 615 (15.42)	73 319 (16.33)
Smoking status, <i>n</i> (%)		
Non-smoker	105 592 (47.02)	229 049 (51.00)
Smoker	37 007 (16.48)	78 505 (17.48)
Ex-smoker	80 244 (35.74)	117 246 (26.11)
Missing	1708 (0.76)	24 301 (5.41)
Ethnicity, <i>n</i> (%)		
White	97 739 (43.53)	186 869 (41.61)
Mixed race	1456 (0.65)	2278 (0.51)
Other	515 (0.23)	852 (0.19)
Black	2987 (1.33)	3442 (0.77)
South Asian	6922 (3.08)	4913 (1.09)
Missing	114 932 (51.18)	250 747 (55.83)

Austria) for the time-dependent analyses; all other analyses were performed using Stata SE 16.1 (StataCorp, College Station, TX, USA). The study protocol was approved by the Scientific Review Committee of the data provider, IQVIA (reference number 20SRC016).

Results

Baseline characteristics


We identified a total of 224 551 exposed patients (incident T2DM) who were matched to 449 101 unexposed patients in the main cohort (study 1: patients with T2DM compared with patients without T2DM). The mean age at the index date of the cohort was 63 years and 56% were male. During the study period, the median follow-up periods were 4.51 years [interquartile range (IQR) 2.01-7.97] and 3.44 years (IQR 1.43-6.61) for the exposed and unexposed groups, respectively. There was a higher proportion of patients who were obese (BMI >30 kg/m²) and in a more deprived socio-economic group in the exposed group than the unexposed group. Baseline characteristics are described in more detail in Table 1.

When examining patients without any history of statin use (study 2), there were 40 879 eligible exposed patients who were matched to 81 757 unexposed patients. The mean age was 61 years and 53% were male. The proportions of other covariates were similar to the main cohort and are also described in Supplementary Table S2, available at *Rheumatology* online. The study population in the time-dependent analysis (study 3) included 191 862 patients who had been prescribed anti-diabetic medication in their record. The mean age was 61 years, 57% were male and the median follow-up of the cohort was 4.8 years. TABLE 2 Crude and adjusted HRs for the risk of RA in patients with diabetes compared with those without diabetes

Characteristics	Exposed (<i>n</i> = 224 551)	Unexposed (<i>n</i> = 449 101)
Outcome events, n (%)	971 (0.43)	2117 (0.47)
Person-years	1 200 042	1 999 301
Crude incidence rate/10 000 py	8.1	10.6
Follow-up years, median (IQR)	4.51 (2.01–7.97)	3.44 (1.43–6.61)
Unadjusted HR (95% CI)	0.78 (0.72, 0.84)	
P-value	<0.01	
Adjusted HR (95% CI)	0.73 (0.67, 0.79)	
P-value	<0.01	

Model was adjusted for sex, age, BMI, Townsend deprivation quintiles, smoking status and ethnicity.

Fig. 1 Forest plot summarizing aHRs of glycaemic control and associated therapies on the risk of RA using time-dependent analysis.



*Metformin with or without other oral drugs. Models were adjusted for sex, age, BMI, estimated glomerular filtration rate (eGFR), systolic blood pressure, Townsend deprivation quintiles, smoking status, ethnicity, peripheral neuropathy, retinopathy, diabetic foot ulcer, hypothyroidism and cardiovascular disease (CVD).

Risk of incident RA

During the study period, there were 971 (IR 8.1/10 000 py) new diagnoses of RA in the exposed group compared with 2117 (IR 10.6/10 000 py) in the unexposed group (Table 2). Following adjustment, this translated into an HR of 0.73 (95% CI 0.67, 0.79). The reduced risk of incident RA in patients with T2DM compared with controls remained significant when male and female patients were analysed separately (Supplementary Table S3, available at *Rheumatology* online). Once we excluded all patients in the analysis who had a history of statin use, the aHR increased to 0.89 (95% CI 0.69, 1.14) and no significant difference was seen between the groups (Supplementary Table S4, available at *Rheumatology* online).

Effects of glycaemic control, anti-diabetic drugs and statins on RA risk

In study 3, we used time-varying covariates to quantify the effects of glycaemic control, anti-diabetic drugs and statins on the incidence of RA. Fig. 1 presents the key results of the main analysis and the sensitivity analysis. There was no evidence of an association between glycaemic control and the development of RA [aHR 1.00 (95% CI 0.99, 1.00)] in patients with T2DM. Compared with other oral drugs only, the use of metformin with or without other oral drugs was not associated with an altered risk of RA [aHR 1.00 (95% CI 0.82, 1.22)]. On the other hand, the use of statins appeared to significantly reduce the risk of RA in patients with diabetes [aHR 0.76 (95% CI 0.66, 0.88)]. Female patients had a significantly higher risk of developing RA [aHR 1.70 (95% CI 1.48, 1.96)], while the effects of unit increase in age [aHR 1.01 (95% CI 1.00, 1.02)] and BMI [aHR 1.01 (95% CI 1.00, 1.02)] were minimal. We also observed a higher risk with smoking, higher comorbidity score and hypothyroidism. Further details on the results are noted in Supplementary Table S5, available at *Rheumatology* online.

In a sensitivity analysis introducing a duration-response analysis for statins use, the aHRs for risk of RA were evident only after 3 years worth of prescriptions [3–4.5 years: aHR 0.77 (95% CI 0.57, 1.05)] and \geq 4.5 years [aHR 0.75 (95% CI 0.57, 0.98)] (Fig. 1 and Supplementary Table S6, available at *Rheumatology* online).

Validation analysis comparing a previous study [30] on the risk of RA in those prescribed DPP4i with and earlier study obtained similar results [aHR 0.94 (95% CI 0.71,1.24)] (Supplementary Table S7, available at *Rheumatology* online).

Discussion

Summary of key findings

To our knowledge, this is the first study to investigate the risk of incident RA in patients with T2DM using a UK population-based cohort. Analysis of this large set of electronic health records suggested that patients with T2DM had a reduced risk of developing RA compared with patients without T2DM. However, subgroup analyses limited to patients who were not on statins identified that this decreased risk of incident RA was largely explained by the use of statins. Our study is the first to examine the effects of longitudinally measured HbA1c, metformin and statins on the incidence of RA using a time-varying covariate approach. Neither glycaemic control nor any of the anti-diabetic medications used, including metformin and DPP4i, influenced the risk of RA in patients with T2DM. The use of statins reduced the risk of RA.

In context with current literature

Our findings conflict with those of Lu *et al.* [25], who observed an increased risk of RA in female patients with T2DM, but they did not control for confounding variables such as BMI and medication use. The present study does not support an association between increased risk of RA in patients with T2DM. In fact, we found a lower incidence that was potentially attributable to the use of statins in patients with T2DM.

Emerging evidence supports the hypothesis that metformin interferes with key immunopathological mechanisms in systemic autoimmune diseases [54]. However, in our study there was absence of an association between metformin use and RA risk. Our finding differs from the results of the study by Naffaa *et al.* [32], who found that adherence to metformin treatment was associated with a decreased risk of RA in female but not male patients. That study measured adherence by calculating the duration of metformin prescription and reporting it as a proportion of the follow-up duration. Furthermore, they did not find a dose-response relationship. Indeed, compared with the lowest adherence group (<20%), the highest adherence group (>80%) had the lowest effect size. However, their study did not fully adjust for BMI, a common risk factor for both T2DM and pro-inflammatory disorders. Adjustment was made for the presence of obesity (BMI $>30 \text{ kg/m}^2$), and obesity was associated with a reduced risk of RA, which contrasts with our findings and those of a recent meta-analysis [55].

Douros *et al.* [30] used a time-varying exposure definition to model the impact of DPP4i on the onset of RA in patients with T2DM using data from another UK primary care database (CPRD). In line with our findings, they showed that the use of DPP4i, compared with other anti-diabetic drugs, was not associated with an altered risk of incident RA [HR 1.0 (95% CI 0.8, 1.3)]. Using US health claims data, one previous study reported a decreased risk of incident RA in DPP4i initiators [aHR 0.66 (95% CI 0.44, 0.99)] when compared with the use of second-line oral anti-diabetic drugs [28]. However, that study had a short duration of follow-up of \sim 9 months and did not account for statin use, which our study suggests is responsible for the apparent decreased risk of RA in patients with T2DM.

A previous systematic review [36] found no difference in the risk of RA in statin users vs non-users, but a lower risk of RA was associated with the use of higher doses of statins or greater persistence with statin treatment. The findings of our study extend this by showing a protective effect of statin use against the progression of RA in those with T2DM and are consistent with evidence for an anti-inflammatory effect of statins. RA is characterized by a progressive chronic inflammatory response associated with high levels of pro-inflammatory cytokines, including TNF- α , IL-1 and IL-6 [1, 6]. Indeed, TNF- α inhibitors are a key group of DMARDs used to limit disease progression in RA [6]. Statin use in patients with established RA has been shown both clinically and experimentally to reduce serum levels of pro-inflammatory cytokines as well as CRP [56-58]. T2DM is also strongly associated with elevated levels of IL-6, CRP and TNF-a, an effect that remains statistically significant even when controlling for BMI [59]. There is also a linear association between glycaemic control and IL-6 levels [59]. It is possible that attenuation of these inflammatory pathways by statins drives the effect we found for patients with T2DM. However, further exploration of these mechanisms is needed [58]. Thus our findings provide justification for a trial to assess whether statins can prevent the development of RA in individuals at high risk of RA and for an increased understanding of the preferences of those at risk of RA for preventive treatment [60].

Strengths and limitations

This study used large sample sizes from the IMRD-UK database, which is generalizable to the UK population. Electronic health records data may be subject to

potential biases resulting from misdiagnoses and inconsistent or incomplete coding of medical conditions. Nevertheless, both RA and diabetes are in the QOF domain, where recording quality is generally high. The prevalence of major chronic conditions in IMRD-UK, adjusted for patient demographics, are also similar to national estimates [37]. On the other hand, there may be residual confounding and therefore the findings should be interpreted cautiously.

Conclusion

RA is a common chronic disease with high personal, societal and healthcare costs. While good disease control can now be achieved in many patients, the inconvenience, risk and expense associated with long-term therapies is considerable. Over the last 10 years there has been an increased focus on understanding risk factors for RA with a view to developing and testing preventive interventions [61, 62]. Understanding the impact on RA onset of other morbid conditions and of commonly used drugs that may have an impact on immune function are thus important. This study found reduced risk of RA in patients with T2DM, but this did not persist when statin users were excluded. The use of metformin and DPP4i did not influence the risk of RA. However, the results suggest that statin use may be associated with a reduced risk of RA, a finding that needs further investigation in a trial setting.

Acknowledgements

K.R., A.F. and J.M.L. are supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. K.N., K.R. and J.M.L. conceived the idea for the study. D.T.Z. and K.M.G. conducted the statistical analysis. D.T.Z. and J.S.C. drafted the manuscript with input from all co-authors. All authors reviewed and approved the final manuscript.

Funding: This article represents independent research funded in part by the Medical Research Council Versus Arthritis Centre for Musculoskeletal Ageing Research.

Disclosure statement: The authors have declared no conflicts of interest.

Data availability statement

The full data set and statistical analysis codes are available from K.N. (k.nirantharan@bham.ac.uk).

Supplementary data

Supplementary data are available at *Rheumatology* online.

References

- 1 Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002;16:707–22.
- 2 Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41:793–800.
- 3 Abhishek A, Doherty M, Kuo CF et al. Rheumatoid arthritis is getting less frequent—results of a nationwide population-based cohort study. Rheumatology (Oxford) 2017;56:736–44.
- 4 Nikiphorou E, de Lusignan S, Mallen CD *et al.* Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. Heart 2020;106:1566–72.
- 5 National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. NG100. London: National Institute for Health and Care Excellence, 2018.
- 6 Smolen JS, Landewe RBM, Bijlsma JWJ *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79:685–99.
- 7 Raza K, Klareskog L, Holers VM. Predicting and preventing the development of rheumatoid arthritis. Rheumatology (Oxford) 2016;55:1–3.
- 8 Zaccardelli A, Friedlander HM, Ford JA, Sparks JA. Potential of lifestyle changes for reducing the risk of developing rheumatoid arthritis: is an ounce of prevention worth a pound of cure? Clin Ther 2019;41: 1323–45.
- 9 Sugiyama D, Nishimura K, Tamaki K et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010;69:70–81.
- 10 Kallberg H, Ding B, Padyukov L et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2011;70:508–11.
- 11 Okada Y, Eyre S, Suzuki A, Kochi Y, Yamamoto K. Genetics of rheumatoid arthritis: 2018 status. Ann Rheum Dis 2019;78:446–53.
- 12 Cotsapas C, Voight BF, Rossin E *et al.* Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet 2011;7:e1002254.
- 13 Liao KP, Gunnarsson M, Kallberg H et al. Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis Rheum 2009;60:653–60.
- 14 Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009;10:43–55.
- 15 Munakata Y, Kodera T, Saito T, Sasaki T. Rheumatoid arthritis, type 1 diabetes, and Graves' disease after acute parvovirus B19 infection. Lancet 2005;366:780.

- 16 Somers EC, Thomas SL, Smeeth L, Hall AJ. Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology 2006;17:202–17.
- 17 Zonana MF, Reyes E, Weisman AK. Coexistence of four autoimmune diseases in one patient: the kaleidoscope of autoimmunity. J Clin Rheumatol 2002;8:322–5.
- 18 Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and metaanalysis. Clin Exp Rheumatol 2015;33:115–21.
- 19 Dubreuil M, Rho YH, Man A *et al.* Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) 2014;53:346–52.
- 20 Movahedi M, Beauchamp ME, Abrahamowicz M *et al.* Risk of incident diabetes mellitus associated with the dosage and duration of oral glucocorticoid therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2016;68:1089–98.
- 21 Ozen G, Pedro S, Holmqvist ME et al. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis 2017;76:848–54.
- 22 Antohe JL, Bili A, Sartorius JA *et al.* Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with antitumor necrosis factor alpha therapy. Arthritis Care Res (Hoboken) 2012;64:215–21.
- 23 Philippou E, Nikiphorou E. Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis. Autoimmun Rev 2018;17:1074–7.
- 24 Tsalamandris S, Antonopoulos AS, Oikonomou E *et al.* The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol 2019;14:50–9.
- 25 Lu MC, Yan ST, Yin WY, Koo M, Lai NS. Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study. PLoS One 2014;9:e101528.
- 26 Lahiri M, Luben RN, Morgan C *et al.* Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register—the EPIC-2-NOAR Study). Ann Rheum Dis 2014;73:219–26.
- 27 Insuela DBR, Carvalho VF. Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds. Eur J Pharmacol 2017;812:64–72.
- 28 Kim SC, Schneeweiss S, Glynn RJ *et al.* Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis 2015;74:1968–75.
- 29 Seong JM, Yee J, Gwak HS. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: a nationwide population-based cohort study. Br J Clin Pharmacol 2019;85:1719–27.
- 30 Douros A, Abrahami D, Yin H *et al.* Use of dipeptidyl peptidase-4 inhibitors and new-onset rheumatoid arthritis in patients with type 2 diabetes. Epidemiology 2018;29: 904–12.

- 31 Zilov AV, Abdelaziz SI, AlShammary A et al. Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes Metab Res Rev 2019;35:e3173.
- 32 Naffaa ME, Rosenberg V, Watad A *et al.* Adherence to metformin and the onset of rheumatoid arthritis: a population-based cohort study. Scand J Rheumatol 2020;49:173–80.
- 33 de Jong HJ, Klungel OH, van Dijk L et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis 2012;71:648–54.
- 34 Chodick G, Amital H, Shalem Y *et al.* Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 2010;7:e1000336.
- 35 Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009;68:546–51.
- 36 Myasoedova E, Karmacharya P, Duarte-Garcia A *et al.* Effect of statin use on the risk of rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2020;50:1348– 56.
- 37 Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011; 19:251–5.
- 38 Ntouva A, Toulis KA, Keerthy D et al. Hypoglycaemia is associated with increased risk of fractures in patients with type 2 diabetes mellitus: a cohort study. Eur J Endocrinol 2019;180:51–8.
- 39 Subramanian A, Adderley NJ, Tracy A *et al.* Risk of incident obstructive sleep apnea among patients with type 2 diabetes. Diabetes Care 2019;42:954–63.
- 40 Toulis KA, Hanif W, Saravanan P *et al.* All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: a population-based, open cohort study. Diabetes Metab 2017;43:211–6.
- 41 Vallerand IA, Lewinson RT, Frolkis AD *et al.* Depression as a risk factor for the development of rheumatoid arthritis: a population-based cohort study. RMD Open 2018;4:e000670.
- 42 Zhang Y, Lu N, Peloquin C *et al.* Improved survival in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis 2017;76:408–13.
- 43 Booth N. What are the read codes? Health Libr Rev 1994;11:177–82.
- 44 Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf 2013;22:64–9.
- 45 Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009;18:76–83.
- 46 Gokhale KM, Chandan JS, Toulis K et al. Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies. Eur J Epidemiol. 2020; 10.1007/s10654-020-00677-6.

- 47 NHS Digital. Quality and Outcomes Framework (QOF) business rules v42 2019–2020 baseline release. https:// digital.nhs.uk/data-and-information/data-collections-anddata-sets/data-collections/quality-and-outcomesframework-qof/quality-and-outcome-framework-qofbusiness-rules/quality-and-outcomes-framework-qofbusiness-rules-v42-2019-2020-baseline-release (8 March 2021, date last accessed).
- 48 McBrien KA, Souri S, Symonds NE et al. Identification of validated case definitions for medical conditions used in primary care electronic medical record databases: a systematic review. J Am Med Inform Assoc 2018;25: 1567–78.
- 49 Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010;340:b5087.
- 50 BMA, NHS Employers, NHS England. 2015/16 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF). Guidance for GMS contract 2015/16. Leeds: NHS Employers, 2015.
- 51 Kontopantelis E, Reeves D, Valderas JM, Campbell S, Doran T. Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study. BMJ Qual Saf 2013;22: 53–64.
- 52 Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in Cox regression models. Ann Transl Med 2018;6:121.
- 53 Therneau T, Grambsch P. Modeling survival data: extending the Cox model. New York: Springer, 2000.

- 54 Ursini F, Russo E, Pellino G *et al.* Metformin and autoimmunity: a "new deal" of an old drug. Front Immunol 2018;9:1236.
- 55 Feng X, Xu X, Shi Y *et al.* Body mass index and the risk of rheumatoid arthritis: an updated dose-response metaanalysis. Biomed Res Int 2019;2019:1–12.
- 56 Abud-Mendoza C, de la Fuente H, Cuevas-Orta E *et al.* Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607–11.
- 57 Kanda H, Hamasaki K, Kubo K *et al.* Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 2002;29:2024–6.
- 58 McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363: 2015–21.
- 59 Mirza S, Hossain M, Mathews C et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine 2012;57:136–42.
- 60 Falahee M, Finckh A, Raza K, Harrison M. Preferences of patients and at-risk individuals for preventive approaches to rheumatoid arthritis. Clin Ther 2019;41:1346–54.
- 61 Al-Laith M, Jasenecova M, Abraham S *et al.* Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials 2019;20:429.
- 62 Gerlag DM, Safy M, Maijer KI *et al.* Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis 2019;78:179–85.